Patents Examined by Nianxiang Zou
  • Patent number: 11684637
    Abstract: Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 27, 2023
    Inventors: Griffith Parks, Alicja Copik
  • Patent number: 11679148
    Abstract: The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: June 20, 2023
    Inventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli, Christophe Desterke
  • Patent number: 11674156
    Abstract: The present invention provides a means for transferring a therapeutic gene of interest into a nervous system cell by a highly-efficient and simpler means. More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector. More specifically, recombinant adeno-associated virus virions, which are capable of passing through the brain-brain barrier, for transferring a therapeutic genes of interest into a nervous system cell in a highly-efficient manner, a drug composition containing the recombinant adeno-associated virus virions, a method for manufacturing the recombinant adeno-associated virus virions, and a kit or the like are provided.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: June 13, 2023
    Assignee: Jichi Medical University
    Inventor: Shinichi Muramatsu
  • Patent number: 11667930
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 6, 2023
    Inventors: Christopher L. Parks, Maoli Yuan, Kevin Wright, Christy Jurgens
  • Patent number: 11655468
    Abstract: Provided is a chemically modified phage display platform and method of use thereof. More specifically, the present disclosure provides a chemically modified phage display library that incorporates 2-acetylphenylboronic acid (APBA) moieties to elicit dynamic covalent binding to the bacterial cell surface. The APBA-modified phage display libraries described herein are applicable to a wide array of bacterial strains and/or mammalian cells, paving the way to facile diagnosis and development of strain-specific antibiotics, and/or peptide-antibiotic conjugates for effective and targeted treatment. Also provided are therapeutic peptides, and pharmaceutical compositions thereof, that are identified by screening the phage display library of the present disclosure, and method of use of such therapeutic peptides for effective and targeted treatment.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: May 23, 2023
    Assignee: The Trustees of Boston College
    Inventor: Jianmin Gao
  • Patent number: 11649437
    Abstract: Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: May 16, 2023
    Inventors: Catherine M. Bollard, Conrad Russell Cruz, Patrick J. Hanley, Michael Keller
  • Patent number: 11643453
    Abstract: The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a polypeptide capable of co-localizing a beta-2 microglobulin component of a MHC class I molecule with an intracellular signalling domain within the cell.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: May 9, 2023
    Inventors: Martin Pulé, James Sillibourne, Lukas Stanczuk
  • Patent number: 11639378
    Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: May 2, 2023
    Assignee: Novartis AG
    Inventors: Johanna Abend, Zorica Dragic, Adam Lloyd Feire, Mark Knapp, Steven Kovacs, Elisabetta Traggiai, Lichun Wang, Yongqiang Wang, Danqing Wu, Qilong Wu, Fangmin Xu
  • Patent number: 11617780
    Abstract: This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: April 4, 2023
    Assignee: SANOFI
    Inventors: Gary J. Nabel, Chih-Jen Wei, Laura Nguyen, Kurt Swanson, Te-Hui Chou, Stefan Koester
  • Patent number: 11608362
    Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 21, 2023
    Assignee: Precigen, Inc.
    Inventors: Douglas E. Brough, Cheryl G. Bolinger, Ramya Yarlagadda, Vinodhbabu Kurella, Prabakaran Ponraj, Simon Metenou, Kuan-Fu Ding
  • Patent number: 11608372
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: March 21, 2023
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic
  • Patent number: 11596685
    Abstract: Compositions are provided comprising messenger RNA constructs having at least one open reading frame (ORF), wherein the ORF is operatively linked to at least one untranslated region (UTR), wherein the UTR comprises at least one organ protection sequence (OPS), wherein the OPS sequence comprises at least a first, a second and a third micro-RNA (miRNA) target sequence, and wherein each of the at least a first, second and third the miRNA target sequences are optimised to hybridise with a corresponding miRNA sequence. The compositions and molecules provided are useful in therapies such as for the treatment of cancer, in immunotherapies, and in vaccines.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 7, 2023
    Assignee: Combined Therapeutics, Inc.
    Inventors: Romain Micol, Valerie Duval
  • Patent number: 11590183
    Abstract: A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 28, 2023
    Inventors: Nicole F. Steinmetz, Karin L. Lee
  • Patent number: 11590219
    Abstract: This disclosure relates to methods of promoting immune responses against HIV and compositions related thereto. In certain embodiments, this disclosure relates to methods of vaccinating for HIV comprising administering to the subject a priming composition followed by a boosting composition. In certain embodiments, the priming composition comprises a recombinant virus such as recombinant MVA that encodes an Env protein of HIV or segment thereof. In certain embodiments, the boosting composition comprises a trimeric cyclically permuted gp120 chimeric protein reported herein or DNA encoding the same.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 28, 2023
    Assignees: Emory University
    Inventors: Rama Rao Amara, Andrew Jones, Raghavan Varadarajan
  • Patent number: 11566061
    Abstract: Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: January 31, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventor: Matthias Stephan
  • Patent number: 11559571
    Abstract: The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: January 24, 2023
    Inventor: Maurizio Paolo Maria Federico
  • Patent number: 11547753
    Abstract: The present invention relates to an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least four different cutaneous HPV genotypes; and to the aforesaid immunogenic polypeptide for use in medicine and for use in vaccination of a subject against cutaneous HPV infection and/or mucosal HPV infection. The present invention further relates to a polynucleotide encoding the aforesaid immunogenic polypeptide and to vectors, host cells, methods for producing an antibody, as well as antibodies related thereto.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 10, 2023
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Martin Müller, Simone Ottonello, Angelo Bolchi, Filipe Mariz, Xueer Zhao, Kathrin Balz
  • Patent number: 11547672
    Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: January 10, 2023
    Inventors: Darrell J. Irvine, Murillo Silva, Shane Crotty, Yu Kato
  • Patent number: 11547694
    Abstract: The present invention relates to methods and compositions for treating human papilloma virus (HPV)-associated diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for treating immune checkpoint blockade resistant diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for enhancing the immune response against an HPV-associated disease using an inhibitor of CXCL12 signaling.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: January 10, 2023
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Jeffrey Gelfand, Sara Pai
  • Patent number: 11542478
    Abstract: This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 3, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Curtis Hewitt, Richard Jude Samulski